{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:35:55Z","timestamp":1772652955438,"version":"3.50.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low-grade B-cell lymphomas (LGBCLs) account for approximately 40% of non-Hodgkin lymphomas with low progression. LGBCL is divided into subgroups, which share common complications. Analyzing prognostic factors and mortality causes could improve patient survival; however, currently available models present limitations in discriminating the cause of death. Therefore, this study aimed to compare the prognostic factors and causes of death, such as secondary malignancies (SMs), aggressive histologic transformation (HT), and infectious complications, including coronavirus disease 2019 (COVID-19), in LGBCLs using a competing risk analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis included 1,047 adults with LGBCLs (follicular lymphoma, 689; marginal zone lymphoma, 312; mantle cell lymphoma [MCL], 46) diagnosed between January 2011 and December 2022 across seven centers. Competing risk models were employed to estimate cumulative incidence rates of lymphoma progression-related and non-lymphoma-related mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with SMs (3.8%) exhibited poorer overall survival than those without SMs, whereas HT and COVID-19 status did not impact survival outcomes in multivariate analysis. Analysis revealed an association of SMs, age\u2009&gt;\u200960 years, male sex, pleural effusion, and elevated lactate dehydrogenase levels with worse non-lymphoma-related mortality. Moreover, age\u2009&gt;\u200960 years, MCL, nodal MZL, and anemia were linked to poorer outcomes for lymphoma progression-related death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The management of non-lymphoma-related risk factors, such as through early SM detection, is crucial for improving the survival of patients with LGBCLs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0328666","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:26:04Z","timestamp":1772648764000},"page":"e0328666","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9559-992X","authenticated-orcid":true,"given":"Tong-Yoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi-June","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seoree","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Won","family":"Jeoung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Sung","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-8200","authenticated-orcid":true,"given":"Youngwoo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"1","key":"pone.0328666.ref001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.beha.2004.08.004","article-title":"Modern histological classification of low grade B-cell lymphomas","volume":"18","author":"A Dogan","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"pone.0328666.ref002","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project","volume":"101","author":"AM Perry","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"pone.0328666.ref003","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"LR Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"45","key":"pone.0328666.ref004","article-title":"Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016: An observational study","volume":"98","author":"J Sim","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"pone.0328666.ref005","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402","volume":"173","author":"ME Williams","year":"2016","journal-title":"Br J Haematol"},{"issue":"28","key":"pone.0328666.ref006","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"BS Kahl","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0328666.ref007","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41408-021-00532-1","article-title":"Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index","volume":"11","author":"Y Wang","year":"2021","journal-title":"Blood Cancer J"},{"key":"pone.0328666.ref008","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/bjh.16492","article-title":"Cause-specific mortality in individuals with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinaemia, 2000-2016","volume":"189","author":"NH Dalal","year":"2020","journal-title":"Br J Haematol"},{"issue":"17","key":"pone.0328666.ref009","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1182\/bloodadvances.2022007990","article-title":"Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study","volume":"6","author":"AM Tun","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"pone.0328666.ref010","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"12","key":"pone.0328666.ref011","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"C Thieblemont","year":"2017","journal-title":"Blood"},{"issue":"13","key":"pone.0328666.ref012","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"E Hoster","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0328666.ref013","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/hon.3128","article-title":"Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database","volume":"41","author":"S Dote","year":"2023","journal-title":"Hematol Oncol"},{"issue":"3","key":"pone.0328666.ref014","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/cam4.5139","article-title":"Secondary malignancies in non-Hodgkin lymphoma survivors: 40\u2009years of follow-up assessed by treatment modality","volume":"12","author":"MW Parsons","year":"2023","journal-title":"Cancer Med"},{"key":"pone.0328666.ref015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2021005691","article-title":"A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study","volume":"6","author":"C Visco","year":"2022","journal-title":"Blood Adv"},{"key":"pone.0328666.ref016","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/bloodadvances.2022007772","article-title":"Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study","volume":"7","author":"S Qi","year":"2023","journal-title":"Blood Adv"},{"key":"pone.0328666.ref017","doi-asserted-by":"crossref","first-page":"705010","DOI":"10.3389\/fonc.2021.705010","article-title":"Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models","volume":"11","author":"A Mosquera Orgueira","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0328666.ref018","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"P Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"27","key":"pone.0328666.ref019","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"BD Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0328666.ref020","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"A Younes","year":"2017","journal-title":"Ann Oncol"},{"key":"pone.0328666.ref021","doi-asserted-by":"crossref","DOI":"10.1002\/9781118445112.stat05798","article-title":"Aalen\u2019s additive regression model.","volume-title":"Statistics Reference Online","author":"OO Aalen","year":"2014"},{"key":"pone.0328666.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/08-AOAS169","article-title":"Random survival forests","volume":"2","author":"H Ishwaran","year":"2008","journal-title":"Ann Appl Stat"},{"key":"pone.0328666.ref023","doi-asserted-by":"crossref","first-page":"103496","DOI":"10.1016\/j.jbi.2020.103496","article-title":"A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models","volume":"108","author":"E Longato","year":"2020","journal-title":"J Biomed Inform"},{"issue":"12","key":"pone.0328666.ref024","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study","volume":"37","author":"IW Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0328666.ref025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"ND Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"1","key":"pone.0328666.ref026","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-023-00903-w","article-title":"A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics","volume":"13","author":"JAA Bult","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"pone.0328666.ref027","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2021006369","article-title":"Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study","volume":"6","author":"J Joelsson","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"pone.0328666.ref028","first-page":"1387","article-title":"Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors","volume":"11","author":"O Kube\u010dek","year":"2021","journal-title":"Life (Basel)"},{"issue":"7","key":"pone.0328666.ref029","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/bloodadvances.2024014840","article-title":"Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35\/10 trial 10-year update","volume":"9","author":"E Kimby","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"pone.0328666.ref030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/fon-2020-0794","article-title":"A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma","volume":"17","author":"M Dreyling","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"pone.0328666.ref031","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"JH Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"pone.0328666.ref032","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000520","article-title":"EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia","volume":"5","author":"B Eichhorst","year":"2020","journal-title":"Hemasphere"},{"issue":"18","key":"pone.0328666.ref033","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"P Morel","year":"2009","journal-title":"Blood"},{"issue":"6","key":"pone.0328666.ref034","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"pone.0328666.ref035","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"G Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"pone.0328666.ref036","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.2022018719","article-title":"Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns","volume":"142","author":"K Dreval","year":"2023","journal-title":"Blood"},{"issue":"5","key":"pone.0328666.ref037","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"A Rinaldi","year":"2011","journal-title":"Blood"},{"issue":"12","key":"pone.0328666.ref038","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"F Nadeu","year":"2020","journal-title":"Blood"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:26:09Z","timestamp":1772648769000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328666"}},"subtitle":[],"editor":[{"given":"Monia","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328666","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}